NasdaqCM:MDXGBiotechs
MiMedx Group (MDXG) Margin Decline Raises Questions on Profitability Narrative
MiMedx Group (MDXG) posted annual earnings growth projections of 15.73% and revenue growth set at 6.7% per year, even as its net profit margin slipped to 10.4% from last year’s 23.2%. Despite a shortfall in earnings growth over the past year, the company has built a solid five-year track record with average annual earnings growth of 67.7% and high-quality current profits. Shares trade at $7.40, notably below the assessed fair value of $16.75. This presents a potential value opportunity, but...